Warnex Inc.
TSX : WNX

Warnex Inc.

February 22, 2011 17:00 ET

Warnex to Serve as Central Laboratory for Genzyme

Warnex Collaborates with Genzyme for its Lysosomal Storage Disorders Testing Program

LAVAL, QUEBEC--(Marketwire - Feb. 22, 2011) - Warnex Inc. (TSX:WNX) announced today that its Warnex Medical Laboratories division will serve as a central laboratory across Canada for Genzyme Canada Inc.'s Lysosomal Storage Disorders Testing Program. This program will assist physicians in diagnosing Fabry (male), Gaucher, Pompe and Mucopolysaccharidosis Type I (MPS I) diseases.

"We are pleased to collaborate with Genzyme to offer this program in Canada, assisting healthcare professionals in the diagnosis of these serious diseases. This collaboration demonstrates our ability to serve as a specialized reference laboratory for hospitals across Canada," said Mark Busgang, President and CEO of Warnex. "In the context of this program, Warnex will perform an enzymatic assay specific to each disease using dried blood spots. This method offers a simple type of sampling procedure that can be easily performed by pricking the finger and applying drops of blood to a blotting paper."

Lysosomal storage disorders (LSDs) are a group of rare inherited metabolic disorders resulting from the malfunction of lysosomes, a specific organelle in the body's cells. The symptoms of lysosomal storage disorders vary, depending on the particular disorder and other variables like the age of onset, and can be mild to severe. If diagnosed late and/or left untreated, patients are at risk of developing significant, irreversible damage and loss of body functions, and life-threatening complications. They can include developmental delay, movement disorders, seizures, dementia, deafness and/or blindness, enlarged livers (hepatomegaly), enlarged spleens (splenomegaly), pulmonary and cardiac problems, and bones that grow abnormally.

"While early diagnosis of these rare diseases is critical, it can be challenging for several reasons. Signs and symptoms of many LSDs often mimic those of other more common diseases and outward characteristics may be subtle and easily overlooked," said Monty Keast, Director of Personalized Genetic Health at Genzyme Canada Inc. "This program aims to facilitate early diagnosis by making blood spot testing available for physicians to use with patients who have symptoms associated with LSDs."

About Genzyme

Celebrating thirteen years in Canada, Genzyme Canada Inc., located in Mississauga, Ontario is the Canadian affiliate of Genzyme Corp., headquartered in Cambridge, Massachusetts. Genzyme Corporation is a biotechnology and health care products company that develops innovative products and services for major unmet medical needs.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex Medical Laboratories provides specialized testing for the healthcare industry as well as pharmaceutical and central laboratory services. Warnex PRO-DNA Services offers DNA identification tests for paternity, maternity and other family relationships, as well as for immigration and forensic testing purposes. Warnex has three facilities located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Contact Information